Literature DB >> 22071913

[Current treatment options in acute myeloid leukemia].

M Heuser1, R F Schlenk, A Ganser.   

Abstract

Genetic aberrations form the basis for diagnostic classification of patients with acute myeloid leukemia (AML) according to the World Health Organization (WHO) classification. Moreover, these aberrations predict response to induction chemotherapy, relapse-free survival, and overall survival of patients with AML. Understanding the pathogenetic role of cytogenetic and molecular changes has led to the development of targeted treatment strategies that require rapid diagnostic assessment of the genetic profile of each patient to select the best treatment available.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22071913     DOI： 10.1007/s00108-011-2929-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


  33 in total

1.  Screens, iron, and leukemia.

Authors:  Richard M Stone; Daniel J DeAngelo
Journal:  Blood       Date:  2009-10-01       Impact factor: 22.113

2.  Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.

Authors:  Katharina Wagner; Frederik Damm; Gudrun Göhring; Kerstin Görlich; Michael Heuser; Irina Schäfer; Oliver Ottmann; Michael Lübbert; Wolfgang Heit; Lothar Kanz; Günter Schlimok; Aruna A Raghavachar; Walter Fiedler; Hartmut H Kirchner; Wolfram Brugger; Manuela Zucknick; Brigitte Schlegelberger; Gerhard Heil; Arnold Ganser; Jürgen Krauter
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

3.  Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.

Authors:  Erdogan Taskesen; Lars Bullinger; Andrea Corbacioglu; Mathijs A Sanders; Claudia A J Erpelinck; Bas J Wouters; Sonja C van der Poel-van de Luytgaarde; Frederik Damm; Jürgen Krauter; Arnold Ganser; Richard F Schlenk; Bob Löwenberg; Ruud Delwel; Hartmut Döhner; Peter J M Valk; Konstanze Döhner
Journal:  Blood       Date:  2010-12-21       Impact factor: 22.113

4.  On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.

Authors:  B Löwenberg; R Zittoun; H Kerkhofs; U Jehn; J Abels; L Debusscher; C Cauchie; M Peetermans; G Solbu; S Suciu
Journal:  J Clin Oncol       Date:  1989-09       Impact factor: 44.544

5.  Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.

Authors:  Utz Krug; Christoph Röllig; Anja Koschmieder; Achim Heinecke; Maria Cristina Sauerland; Markus Schaich; Christian Thiede; Michael Kramer; Jan Braess; Karsten Spiekermann; Torsten Haferlach; Claudia Haferlach; Steffen Koschmieder; Christian Rohde; Hubert Serve; Bernhard Wörmann; Wolfgang Hiddemann; Gerhard Ehninger; Wolfgang E Berdel; Thomas Büchner; Carsten Müller-Tidow
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

6.  Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.

Authors:  Hagop Kantarjian; Farhad Ravandi; Susan O'Brien; Jorge Cortes; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; William Wierda; Tapan Kadia; Sherry Pierce; Jianqin Shan; Michael Keating; Emil J Freireich
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

7.  High-dose daunorubicin in older patients with acute myeloid leukemia.

Authors:  Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

8.  Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.

Authors:  Richard F Schlenk; Konstanze Döhner; Michael Kneba; Katharina Götze; Frank Hartmann; Francesco Del Valle; Heinz Kirchen; Elisabeth Koller; Jörg T Fischer; Lars Bullinger; Marianne Habdank; Daniela Späth; Silja Groner; Bernhard Krebs; Sabine Kayser; Andrea Corbacioglu; Andreas Anhalt; Axel Benner; Stefan Fröhling; Hartmut Döhner
Journal:  Haematologica       Date:  2008-12-04       Impact factor: 9.941

9.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Authors:  Peter Paschka; Richard F Schlenk; Verena I Gaidzik; Marianne Habdank; Jan Krönke; Lars Bullinger; Daniela Späth; Sabine Kayser; Manuela Zucknick; Katharina Götze; Heinz-A Horst; Ulrich Germing; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 50.717

10.  Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

Authors:  Felicitas Thol; Frederik Damm; Katharina Wagner; Gudrun Göhring; Brigitte Schlegelberger; Dieter Hoelzer; Michael Lübbert; Wolfgang Heit; Lothar Kanz; Günter Schlimok; Aruna Raghavachar; Walter Fiedler; Hartmut Kirchner; Gerhard Heil; Michael Heuser; Jürgen Krauter; Arnold Ganser
Journal:  Blood       Date:  2010-04-26       Impact factor: 25.476
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.